BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180426
DTEND;VALUE=DATE:20180528
DTSTAMP:20260730T042814
CREATED:20180426T072408Z
LAST-MODIFIED:20180426T072534Z
UID:19935-1524700800-1527465599@ces.b2sg.org
SUMMARY:Post Doctoral Fellow (NCI)
DESCRIPTION:The Division of Cancer Treatment & Diagnosis (DCTD)\, National Cancer Institute is actively exploring drug molecular mechanisms in conjunction with tumor gene expression\, mutation and protein profiling to pair the development of newer anticancer agents with specific molecular vulnerabilities in the precision oncology medicine setting. The Leidos Biomedical program in molecular pharmacology at the Frederick National Laboratory for Cancer Research\, NCI-Frederick campus\, supports the Molecular Pharmacology Branch pursuit of this DCTD initiative in the Developmental Therapeutics Program (DTP). \nKEY ROLES/RESPONSIBILITIES \nThe Post Doctoral Fellow will: \n\nPlay a key role in evaluating the associations between aMOIs\, genes of interest\, and drug responses in the context of targeted clinical trials using cancer cell lines\, Patient Derived Xenografts (PDX) lines and organoid cultures\, by applying several molecular biology techniques to achieve gene modulation\nExecute experimental procedures according to project plans and as agreed with the Laboratory Head\nPerform knock-down (using siRNA and shRNA) as well over-expression experiments to evaluate the impact of genes of interest in the sensitivity or resistant to drug treatment\n\n\nQualifications: \nBASIC QUALIFICATIONS \nTo be considered for this position\, you must minimally meet the knowledge\, skills\, and abilities listed below: \n\nPossession of a Doctoral degree from an accredited college or university according to the Council for Higher Education Accreditation in a field related to pharmacology\, molecular pharmacology\, experimental therapeutics\, cancer therapy or drug development. Foreign degrees will be evaluated for U.S. equivalency\nNo additional experience required for candidates with a Doctoral degree\nMust be able to obtain and maintain a security clearance\n\nPREFERRED QUALIFICATIONS \nCandidates with these desired skills will be given preferential consideration: \n\nExperience in epigenetics\nExperience applying molecular biological techniques including gene editing methodologies to the resolution of cancer drug mechanism of action questions\nExpertise using gene expression/mutations profiles to identify genes\, proteins and pathways that determine drug sensitivity\n\nExpected Competencies: \n\nThe candidate must have practical experience with basic molecular and cellular biology techniques including PCR cloning\, mutagenesis\, transient and stable expression methodologies and si/shRNA mediated gene knockdown\nAbility to effectively interpret experimental data and sufficient experience with molecular pharmacology and its methodologies to determine compounds mechanisms of action are required\nMust have a thorough understanding of genetics\, genomics and gene regulation\nExperience with viral expression systems is required
URL:https://ces.b2sg.org/event/leidos-26apr18/
LOCATION:Leidos Biomedical\, 5202 Presidents Ct\, Frederick\, MD\, 21703\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/04/leidos.jpg
END:VEVENT
END:VCALENDAR